Internal medicine

Tumor microenvironment

Immunotherapy

FOXP3

Cancer immunotherapy

Bioinformatics

Biology

Cancer

Oncology

Immunohistochemistry

Immunology

CD68

Multiplex

Biomarker

Cancer research

Biochemistry

Medicine

Immune system

Nature Communications

A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the tumour microenvironment. The predictive value of tumour-infiltrating immune cells (TIICs) has not been definitively established with regard to their density and spatial organisation. Here, multiplex immunohistochemistry is used to quantify in situ biomarkers at sub-cellular resolution in 80 patients with GC. To predict the response to immunotherapy, we establish a multi-dimensional TIIC signature by considering the density of CD4 + FoxP3 − PD-L1 + , CD8 + PD-1 − LAG3 − , and CD68 + STING + cells and the spatial organisation of CD8 + PD-1 + LAG3 − T cells. The TIIC signature enables prediction of the response of patients with GC to anti-PD-1/PD-L1 immunotherapy and patient survival. Our findings demonstrate that a multi-dimensional TIIC signature may be relevant for the selection of patients who could benefit the most from anti-PD-1/PD-L1 immunotherapy.

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment